Litigation Details for IN RE: Ozempic (Semaglutide) Patent Litigation (J.P.M.L. 2022)

✉ Email this page to a colleague

Docket	⤷ Sign Up	Date Filed	2022-05-06
Court	United States Judicial Panel on Multidistrict Litigation	Date Terminated
Cause		Assigned To	Colm F. Connolly
Jury Demand		Referred To
Patents	10,220,155; 10,335,462; 10,357,616; 10,376,652; 8,114,833; 8,129,343; 8,536,122; 8,684,969; 8,920,383; 9,108,002; 9,132,239; 9,457,154; 9,616,180; 9,687,611; 9,775,953; 9,861,757; RE46,363
Link to Docket	External link to docket

The small molecule drugs covered by the patents cited in this case are ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , and ⤷ Sign Up .

Subscribe to access the full database, or Sign Up
Date Filed	Document No.	Description	Snippet	Link To Document
0000-00-00				External link to document
2022-05-31	20		   11 10,220,155*   …eighteen patents against MPI. Eight of those patents, containing a total of 125 unique patent claims, …method of treatment patent (the ’462 patent). Id. Any common issues for one asserted patent cannot outweigh…While Novo asserts some of those patents in Delaware, eight patents are asserted exclusively against …disputes regarding patent infringement or validity before the generic drug is sold. If the patent-holder initiates	External link to document
2022-08-05	29		; 9,616,180; 9,687,611; 9,775,953; 9,861,757; 10,220,155; 10,335,462; 10,357,616; 10,376,652; and 11,097,063… infringed two or more of the Ozempic patents. While the patents asserted in each action vary somewhat…Valsartan) Patent Litig., 437 F. Supp. 3d 1372, 1373 (J.P.M.L. 2020); In re Palbociclib Patent Litig., 396…unique patents, this may be a temporary distinction. Further, many of the “non-common” patents asserted…West Virginia action derive from the same patent family as patents asserted in the Delaware actions, and	External link to document
>Date Filed	>Document No.	>Description	>Snippet	>Link To Document